Macrocyclic contrast agents for magnetic resonance imaging of chronic myocardial infarction: Intraindividual comparison of gadobutrol and gadoterate meglumine

European Radiology

Volumn 23, Issue 1, 2013, Pages 108-114

  Wagner, Moritz ^a   Schilling, Rene ^a   Doeblin, Patrick ^a   Huppertz, Alexander ^a   Luhur, Reny ^a   Schwenke, Carsten ^b   Maurer, Martin ^a   Hamm, Bernd ^a   Taupitz, Matthias ^a   Durmus, Tahir ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SCO:SSiS Statistical Consulting   (Germany)

Author keywords

Cardiac; Contrast agent; Humans; Magnetic resonance imaging; Myocardial infarction

Indexed keywords

GADOBUTROL; GADOTERATE MEGLUMINE;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; AGED; CHRONIC DISEASE; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; MYOCARDIAL INFARCTION; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84871297161     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-012-2563-6     Document Type: Article

References (32)

1. Wagner A, Mahrholdt H, Holly TA et al (2003) Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 361:374-379 (Pubitemid 36164969)
2. Judd RM, Lugo-Olivieri CH, Arai M et al (1995) Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation 92:1902-1910
3. Wesbey GE, Higgins CB, McNamara MT et al (1984) Effect of gadolinium-DTPA on the magnetic relaxation times of normal and infarcted myocardium. Radiology 153:165-169 (Pubitemid 14043402)
4. Simonetti OP, Kim RJ, Fieno DS et al (2001) An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218:215-223 (Pubitemid 32151298)
5. Wong DT, Richardson JD, Puri R et al (2012) The role of cardiac magnetic resonance imaging following acute myocardial infarction. Eur Radiol. doi: 10.1007/s00330-012-2420-7
6. Kim RJ, Chen EL, Lima JA, Judd RM (1996) Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation 94:3318-3326 (Pubitemid 26427504)
7. McNamara MT, Higgins CB, Ehman RL, Revel D, Sievers R, Brasch RC (1984) Acute myocardial ischemia: magnetic resonance contrast enhancement with gadolinium-DTPA. Radiology 153:157-163 (Pubitemid 14043401)
8. Pereira RS, Prato FS, Wisenberg G, Sykes J (1996) The determination of myocardial viability using Gd-DTPA in a canine model of acute myocardial ischemia and reperfusion. Magn Reson Med 36:684-693 (Pubitemid 26376706)
9. de Roos A, van Rossum AC, van der Wall E et al (1989) Reperfused and nonreperfused myocardial infarction: diagnostic potential of Gd-DTPA-enhanced MR imaging. Radiology 172:717-720 (Pubitemid 19211591)
10. Goetti R, Feuchtner G, Stolzmann P et al (2011) Delayed enhancement imaging of myocardial viability: low-dose high-pitch CT versus MRI. Eur Radiol 21:2091-2099
11. Gerbaud E, Montaudon M, Leroux L et al (2008) MRI for the diagnosis of left ventricular apical ballooning syndrome (LVABS). Eur Radiol 18:947-954
12. Comte A, Kastler B, Laborie L, Hadjidekov G, Meneveau N, Boulahdour H (2008) Using a contrast-enhanced imaging sequence at 3-minute delay in 3-T magnetic resonance imaging for acute infarct evaluation. Invest Radiol 43:669-675
13. Matsumoto H, Matsuda T, Miyamoto K et al (2010) Late gadolinium-enhanced cardiovascular MRI at end-systole: feasibility study. AJR Am J Roentgenol 195:1088-1094
14. Leurent G, Langella B, Fougerou C et al (2011) Diagnostic contributions of cardiac magnetic resonance imaging in patients presenting with elevated troponin, acute chest pain syndrome and unobstructed coronary arteries. Arch Cardiovasc Dis 104:161-170
15. Meyer C, Strach K, Thomas D et al (2008) High-resolution myocardial stress perfusion at 3 T in patients with suspected coronary artery disease. Eur Radiol 18:226-233 (Pubitemid 351234042)
16. Pujadas S, Vidal-Perez R, Hidalgo A et al (2010) Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy: a cardiac magnetic resonance imaging study. Eur J Radiol 75:e88-e91
17. Thiele H, Hildebrand L, Schirdewahn C et al (2010) Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) trial. J Am Coll Cardiol 55:2201-2209
18. Lonborg J, Vejlstrup N, Mathiasen AB, Thomsen C, Jensen JS, Engstrom T (2011) Myocardial area at risk and salvage measured by T2-weighted cardiovascular magnetic resonance: reproducibility and comparison of two T2-weighted protocols. J Cardiovasc Magn Reson 13:50
19. Durmus T, Schilling R, Doeblin P et al (2012) Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine. Invest Radiol 47:183-188
20. Bondarenko O, Beek AM, Hofman MB et al (2005) Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson 7:481-485 (Pubitemid 40563339)
21. Ortiz-Perez JT, Rodriguez J, Meyers SN, Lee DC, Davidson C, Wu E (2008) Correspondence between the 17-segment model and coronary arterial anatomy using contrast-enhanced cardiac magnetic resonance imaging. JACC Cardiovasc Imaging 1:282-293 (Pubitemid 351688327)
22. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310 (Pubitemid 16134762)
23. Masoudi FA, Plomondon ME, Magid DJ, Sales A, Rumsfeld JS (2004) Renal insufficiency and mortality from acute coronary syndromes. Am Heart J 147:623-629 (Pubitemid 38900446)
24. Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann HJ (2008) Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 43:817-828
25. Rofsky NM, Sherry AD, Lenkinski RE (2008) Nephrogenic systemic fibrosis: a chemical perspective. Radiology 247:608-612
26. Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W (2009) Risk factors for NSF: a literature review. J Magn Reson Imaging 30:1298-1308
27. Chrysochou C, Buckley DL, Dark P, Cowie A, Kalra PA (2009) Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging 29:887-894
28. Altun E, Semelka RC, Cakit C (2009) Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol 16:897-905
29. Bauner KU, Reiser MF, Huber AM (2009) Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine. Invest Radiol 44:95-104
30. Schlosser T, Hunold P, Herborn CU et al (2005) Myocardial infarct: depiction with contrast-enhanced MR imaging-comparison of gadopentetate and gadobenate. Radiology 236:1041-1046 (Pubitemid 41170871)
31. Balci NC, Inan N, Anik Y, Erturk MS, Ural D, Demirci A (2006) Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging. Acad Radiol 13:833-839 (Pubitemid 43866530)
32. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 40:715-724 (Pubitemid 41546838)